Literature DB >> 2356855

Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease.

M E Kadin1, B A Agnarsson, L R Ellingsworth, S R Newcom.   

Abstract

Transforming growth factor beta (TFG-beta) is a multifunctional growth factor that promotes the growth of fibroblasts, collagen synthesis and angiogenesis, and stimulates monocyte migration and activation, but suppresses the growth and differentiation of immune lymphocytes and killer cells. Previously we demonstrated biologic activity for TGF-beta in supernatants of fresh Hodgkin's disease (HD) cell cultures and the cell line L428 derived from nodular sclerosing HD. This study was undertaken to find evidence of TGF-beta activity directly in tissues affected by HD. Formalin-fixed tissue from 14 patients with HD, including 8 nodular sclerosis, 4 mixed cellularity, 1 lymphocyte predominance, and 1 lymphocyte depletion type were studied by immunoperoxidase technique with antibody CC (1-30) raised against a synthetic polypeptide with the same N-terminal amino acid sequence as TGF-beta 1. Transforming growth factor beta activity was demonstrated in six cases of nodular sclerosis but not in other histologic types of HD. Staining for TGF-beta was found in the cytoplasm of Reed-Sternberg (RS) cells in one case and on the surface of RS cells and their lacunar variants in five cases. Transforming growth factor beta activity associated with the extracellular matrix was localized mainly around blood vessels, zones of necrosis, at the margins of bands of collagen sclerosis, and in areas containing syncytia of RS cells. In two cases TGF-beta was associated with collections of epithelioid histiocytes or granulomas. Small lymphocytes, granulocytes, and germinal center cells were unreactive. These results suggest that TGF-beta is a growth factor of biologic importance in HD and may be responsible for many of the histologic features, such as nodular sclerosis and granulomas, that may have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2356855      PMCID: PMC1877568     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.

Authors:  A B Roberts; M B Sporn; R K Assoian; J M Smith; N S Roche; L M Wakefield; U I Heine; L A Liotta; V Falanga; J H Kehrl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

Authors:  S M Wahl; D A Hunt; L M Wakefield; N McCartney-Francis; L M Wahl; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 3.  Impact of Hodgkin's disease upon the immune system.

Authors:  J J Twomey; L Rice
Journal:  Semin Oncol       Date:  1980-06       Impact factor: 4.929

4.  Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases.

Authors:  K Sheibani; C D Winberg; S van de Velde; D W Blayney; H Rappaport
Journal:  Am J Pathol       Date:  1987-04       Impact factor: 4.307

5.  Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors.

Authors:  R Derynck; D V Goeddel; A Ullrich; J U Gutterman; R D Williams; T S Bringman; W H Berger
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

6.  Potentiation of fibroblast growth by nodular sclerosing Hodgkin's disease cell cultures.

Authors:  S R Newcom; L O'Rourke
Journal:  Blood       Date:  1982-07       Impact factor: 22.113

7.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.

Authors:  A H Rook; J H Kehrl; L M Wakefield; A B Roberts; M B Sporn; D B Burlington; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

8.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

9.  Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

Authors:  C Knabbe; M E Lippman; L M Wakefield; K C Flanders; A Kasid; R Derynck; R B Dickson
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  18 in total

1.  Hodgkin's lymphoma associated with myelofibrosis: A case report.

Authors:  Rong Fu; Hong Yu; Yu-Hong Wu; Hui Liu; Zong-Hong Shao
Journal:  Oncol Lett       Date:  2015-06-30       Impact factor: 2.967

Review 2.  Hodgkin's disease--I: Identification and classification.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-11

3.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 4.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

5.  Nucleoli and AgNORs in Hodgkin's disease.

Authors:  N N Mamaev; N V Medvedeva; V F Shust; A B Markochev; N D Pasternak
Journal:  Mol Pathol       Date:  1997-06

Review 6.  Molecular pathogenesis of Hodgkin lymphoma.

Authors:  Momoko Nishikori; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

7.  Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease.

Authors:  L R Zukerberg; A B Collins; J A Ferry; N L Harris
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

8.  In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.

Authors:  B Jahn; J Brieger; K Fenchel; P S Mitrou; L Bergmann
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

9.  Constitutive expression of tenascin in T-dependent zones of human lymphoid tissues.

Authors:  M Chilosi; M Lestani; A Benedetti; L Montagna; S Pedron; A Scarpa; F Menestrina; S Hirohashi; G Pizzolo; G Semenzato
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

10.  Role of mast cells in fibrosis of classical Hodgkin lymphoma.

Authors:  Shoko Nakayama; Taiji Yokote; Nobuya Hiraoka; Uta Nishiwaki; Toshiaki Hanafusa; Yasuichiro Nishimura; Motomu Tsuji
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-19       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.